The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells

被引:25
作者
Arnott, Clare [1 ,2 ]
Punnia-Moorthy, Gaya [3 ]
Tan, Joanne [2 ,3 ]
Sadeghipour, Sara [2 ,3 ]
Bursill, Christina [2 ,3 ]
Patel, Sanjay [1 ,2 ,3 ]
机构
[1] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Heart Res Inst, Sydney, NSW, Australia
来源
PLOS ONE | 2016年 / 11卷 / 03期
关键词
NF-KAPPA-B; ARTERIAL THROMBOEMBOLIC EVENTS; RANDOMIZED CONTROLLED-TRIALS; MACULAR DEGENERATION; VEGF-TRAP; CARDIOVASCULAR SAFETY; BEVACIZUMAB; MECHANISMS; CHEMOKINES; THERAPY;
D O I
10.1371/journal.pone.0150688
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction Recent studies have suggested that the VEGF inhibitors, Ranibizumab and Aflibercept may be associated with an excess of cardiovascular events, potentially driven by increasing atheroma instability, leading to plaque rupture and clinical events. Inflammation plays a key role in the progression of atherosclerotic plaque and particularly conversion to an unstable phenotype. Here, we sought to assess the in vitro effects of these drugs on the expression of key inflammatory mediators on endothelial cells. Methods Human coronary artery endothelial cells were co-incubated for 16h with Ranibizumab (0.11nM) or Aflibercept (0.45nM), as determined by each drug's peak serum concentration (Cmax). Expression at protein (ELISA) and gene (RT-PCR) level of inflammatory chemokines CCL2, CCL5 and CXC3L1 as well as gene expression for the cell adhesion molecules VCAM-1, ICAM-1 and the key NF-kappa b protein p65 was assessed. VEGF-A protein levels were also determined. Results Both drugs significantly increased chemokine, cell adhesion molecule (CAM) and p65 expression, while decreasing VEGF-A protein secretion. At equivalent Cmax concentrations, Aflibercept was significantly more pro-inflammatory than Ranibizumab. Reduction of secreted VEGF-A levels significantly attenuated inflammatory effects of both drugs, whereas blockade of the VEGF-A receptor or silencing of VEGF-A gene synthesis alone had no effect, suggesting that binding of drug to secreted VEGF-A is crucial in promoting inflammation. Finally, blockade of Toll-like receptor 4 significantly reduced inflammatory effects of both drugs. Conclusion We demonstrated here, for the first time, that both drugs have potent pro-inflammatory effects, mediated via activation of Toll-like receptor 4 on the endothelial cell surface by drug bound to VEGF-A. Further studies are required to investigate whether these effects are also seen in vivo.
引用
收藏
页数:15
相关论文
共 36 条
  • [1] The role of vascular endothelial growth factor \in ocular health and disease
    Adamis, AP
    Shima, DT
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (02): : 111 - 118
  • [2] Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
    Avery, Robert L.
    Castellarin, Alessandro A.
    Steinle, Nathan C.
    Dhoot, Dilsher S.
    Pieramici, Dante Joseph
    See, Robert
    Couvillion, Stephen
    Nasir, Ma'an A.
    Rabena, Melvin D.
    Le, Kha
    Maia, Mauricio
    Visich, Jennifer E.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (12) : 1636 - 1641
  • [3] What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
    Avery, Robert L.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 : 7 - 10
  • [4] Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-κB
    Bhavsar, Pankaj K.
    Sukkar, Maria B.
    Khorasani, Nadia
    Lee, Kang-Yun
    Chung, Kian Fan
    [J]. FASEB JOURNAL, 2008, 22 (06) : 1807 - 1816
  • [5] Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
  • [6] CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS
    Bressler, Neil M.
    Boyer, David S.
    Williams, David F.
    Butler, Steven
    Francom, Steven F.
    Brown, Benton
    Di Nucci, Flavia
    Cramm, Timothy
    Tuomi, Lisa L.
    Ianchulev, Tsontcho
    Rubio, Roman G.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (09): : 1821 - 1828
  • [7] Bursi CA, 2004, CURR OPIN LIPIDOL, V15, P145, DOI [10.1097/00041433-200404000-00007, 10.1097/01.mol.0000124526.75650.13]
  • [8] High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo
    Bursill, Christina A.
    Castro, Maria L.
    Beattie, Douglas T.
    Nakhla, Shirley
    van der Vorst, Emiel
    Heather, Alison K.
    Barter, Philip J.
    Rye, Kerry-Anne
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (09) : 1773 - U223
  • [9] Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis
    Campbell, Robert J.
    Bell, Chaim M.
    Paterson, J. Michael
    Bronskill, Susan E.
    Moineddin, Rahim
    Whitehead, Marlo
    Gill, Sudeep S.
    [J]. OPHTHALMOLOGY, 2012, 119 (08) : 1604 - 1608
  • [10] Targeted pharmacotherapy of retinal diseases with ranibizumab
    Campochiaro, Peter A.
    [J]. DRUGS OF TODAY, 2007, 43 (08) : 529 - 537